查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
陣發性睡眠性血紅蛋白尿藥物市場，按治療、按藥物、按給藥途徑、最終用戶、按國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1351435

陣發性睡眠性血紅蛋白尿藥物市場，按治療、按藥物、按給藥途徑、最終用戶、按國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment, By Drugs, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 281 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年陣發性睡眠性血紅素尿症藥物市場規模為34.702億美元，2023年至2030年年複合成長率為13.8%。

陣發性睡眠性血紅素尿藥市場 - 市場動態：

  • 不斷成長的監管批准和研發推動市場成長
  • 全球陣發性睡眠性血紅蛋白尿藥物市場的發展在很大程度上取決於歐洲藥品管理局（EMA）、美國食品藥物管理局（FDA）以及其他國際監管機構等組織的監管批准。 Eculizumab和ravulizumab的市場佔有率和患者可近性受益於它們的批准，奠定了堅實的基礎。此外，嘗試發現新的治療替代方案並增強現有療法是 PNH 領域持續研究和開發的主要目標。這包括研究組合藥物、開發創新的標靶療法和替代給藥技術。這些發展和突破有助於PNH藥品產業的擴大和發展。

陣發性睡眠性血紅蛋白尿藥物市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，全球陣發性睡眠性血紅蛋白尿藥物市場預計在預測期內（2023-2030）每年將以 13.8% 左右的年複合成長率成長
  • 由於監管部門批准的不斷增加，陣發性睡眠性血紅蛋白尿藥物產業預計將以顯著的速度成長
  • 根據治療，輸血領域預計將在預測期內主導市場
  • 從地區來看，預計北美將在預測期內主導市場

陣發性睡眠性血紅素尿症藥物市場-細分分析：

  • 全球陣發性睡眠性血紅蛋白尿藥物市場根據治療、藥物、給藥途徑、最終用戶和地區進行細分。
  • 根據治療，市場分為藥物、補充劑、輸血和骨髓移植。預計輸血領域將在預測期內主導市場。輸血是可能有助於減輕貧血症狀的療法之一。 PNH 會引起包括血栓形成在內的嚴重不良影響，如果不及時治療可能會致命。 PNH 患者經常需要輸血來治療貧血症狀，因為在輸血過程中，患者會接受捐贈者的血液或血液製品。從而推動市場成長。

陣發性睡眠性血紅素尿症藥物市場-地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。預計北美將在預測期內主導市場。開發和推廣 PNH 標靶治療的主要製藥公司主導了該地區的 PNH 藥物市場。像 Alexion Pharmaceuticals（現在是阿斯特捷利康的一個部門）和藥物 eculizumab（以 Soliris 名稱銷售）這樣的公司對市場環境產生了重大影響。此外，PNH 藥物的批准和供應很大程度上受到北美（尤其是美國）監管環境的影響。治療PNH 的標靶藥物，如依庫珠單抗(eculizumab) 和拉維珠單抗(ravulizumab)（以Ultomiris 品牌上市）已獲得美國食品藥物管理局(FDA) 的批准，有助於其在該領域的廣泛使用。

陣發性睡眠性血紅素尿藥市場-競爭格局：

全球深水碳氫化合物探勘市場的領先公司正在加強研發力度，以實現產品多元化。此外，這些市場參與者利用策略聯盟和合作夥伴關係來促進成長。市場上的主要參與者包括 Ra Pharmaceuticals Inc、CinnaGen Co、Akari Therapeutics Plc、Alexion Pharmaceuticals Inc、Apellis Pharmaceuticals、Abbott、NorthStar Rx LLC、Alnylam Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Novartis AG、Regeneron Pharmaceuticals Inc、F.offmann-La Roche Ltd、Novartis AG、Regeneron Pharmaceuticals Inc. BIOCAD、Samsung Bioepis、Amyndas Pharmaceuticals、Teva Pharmaceutical Industries Ltd.、LGM Pharma.、Lannett、Achillion Pharmaceuticals Inc 與Amgen Inc.

最近的發展：

據中外製藥稱，2023 年9 月，美國食品和藥物管理局(FDA) 批准了crovalimab 的生物製劑許可申請(BLA)，crovalimab 是一種實驗性全新抗C5 循環單株抗體，用於治療陣發性睡眠性血紅蛋白尿症(PNH) 此次接受是基於關鍵的III 期COMMODORE 2 研究結果，該研究結果表明Crovalimab 有效控制了疾病，並且在PNH 患者中具有良好的耐受性。1 Crovalimab 的持續獲益風險概況如III 期COMMODORE 1 研究中所示研究結果為此應用提供了額外的證據。

目錄

第 1 章：陣發性睡眠性血紅素尿藥市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 陣發性睡眠性血紅素尿藥市場片段（依治療）
    • 陣發性睡眠性血紅素尿藥市場片段（依藥物）
    • 陣發性睡眠性血紅素尿藥市場片段（依給藥途徑）
    • 最終用戶的陣發性睡眠性血紅蛋白尿藥物市場片段
    • 陣發性睡眠性血紅素尿藥市場片段（依國家/地區）
    • 按地區分類的陣發性睡眠性血紅素尿藥市場片段
  • 競爭洞察

第 3 章：陣發性睡眠性血紅素尿藥主要市場趨勢

  • 陣發性睡眠性血紅素尿藥市場促進因素
    • 市場促進因素的影響分析
  • 陣發性睡眠性血紅素尿藥市場限制
    • 市場限制影響分析
  • 陣發性睡眠性血紅素尿藥市場機會
  • 陣發性睡眠性血紅素尿藥市場未來趨勢

第 4 章：陣發性睡眠性血紅素尿藥物工業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：陣發性睡眠性血紅素尿藥市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：陣發性睡眠性血紅素尿藥市場格局

  • 2022 年陣發性睡眠性血紅素尿藥市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：陣發性睡眠性血紅素尿藥市場 - 依治療分類

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 藥物
    • 補充品
    • 輸血
    • 骨髓移植

第 8 章：陣發性睡眠性血紅素尿藥市場 - 依藥物分類

  • 概述
    • 按藥品分類的細分市場佔有率分析
    • 依庫珠單抗
    • 拉維利珠單抗
    • 其他

第 9 章：陣發性睡眠性血紅素尿藥市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 注射用

第 10 章：陣發性睡眠性血紅蛋白尿藥物市場 - 依最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 居家護理
    • 專科診所
    • 其他

第 11 章：陣發性睡眠性血紅素尿藥市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 陣發性睡眠性血紅素尿症藥物北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模與預測（以不同處理方式）
    • 北美市場規模和預測（按藥品）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲陣發性睡眠性血紅素尿症藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按處理方式）
    • 歐洲市場規模與預測（按藥品）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區陣發性睡眠性血紅素尿症藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（以不同處理方式）
    • 亞太地區藥品市場規模及預測
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲陣發性睡眠性血紅素尿症藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（以不同處理方式）
    • 拉丁美洲市場規模與預測（按藥品）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲陣發性睡眠性血紅素尿藥主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東及非洲市場規模及預測（依不同處理方式）
    • 中東和非洲市場規模及預測（按藥品）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 陣發性睡眠性血紅素尿藥物產業

  • 競爭儀表板
  • 公司簡介
    • Ra Pharmaceuticals Inc
    • CinnaGen Co
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Apellis Pharmaceuticals
    • Abbott
    • NorthStar Rx LLC
    • Alnylam Pharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • BIOCAD
    • Samsung Bioepis
    • Amyndas Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd.
    • LGM Pharma.
    • Lannett
    • Achillion Pharmaceuticals Inc
    • Amgen Inc

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1670

REPORT HIGHLIGHT

Paroxysmal Nocturnal Hemoglobinuria Drug Market size was valued at USD 3,470.2 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.

Red blood cells are destroyed (hemolyzed) and aberrant red blood cells are present in the circulation in paroxysmal nocturnal hemoglobinuria (PNH), an uncommon and possibly fatal blood condition. It results from excessive activation of the complement system, a component of the immune system in charge of removing foreign substances in the body, which is brought on by a genetic mutation that affects the proteins on the surface of red blood cells.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Market Dynamics:

  • Growing regulatory approvals and R&D drives market growth
  • The developments of the worldwide paroxysmal nocturnal hemoglobinuria medicine market heavily depend on regulatory approvals from organizations like the European Medicines Agency (EMA), the U.S. Food and medicine Administration (FDA), and other international regulatory agencies. Eculizumab and ravulizumab's market presence and patient accessibility have benefited from their approval, which has laid a solid basis. Additionally, attempts to discover novel therapy alternatives and enhance existing therapies are the main goals of continuing research and development in the field of PNH. This includes investigating combination medicines, developing innovative targeted therapeutics, and alternate administration techniques. These developments and breakthroughs help the PNH drugs industry expand and develop.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Paroxysmal Nocturnal Hemoglobinuria Drug market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)
  • The Paroxysmal Nocturnal Hemoglobinuria Drug industry is projected to grow at a significant rate owing to the growing regulatory approvals
  • Based on treatment, the blood transfusion segment is expected to dominate the market over the forecast period
  • Based on region, North America is expected to dominate the market over the forecast period

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:

  • The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market is segmented based on treatment, drugs, route of administration, end user, and Region.
  • Based on treatment, the market is bifurcated into medication, supplements, blood transfusion, and bone marrow transplants. The blood transfusion segment is expected to dominate the market over the forecast period. Blood transfusion is one of the therapies that might help to lessen the symptoms of anemia. PNH causes major adverse effects including thrombosis and can be deadly if left untreated. PNH patients frequently require blood transfusions to treat their anemic symptoms because, during a transfusion, the patients receive blood or blood products from a donor. Thus, driving the market growth.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. Major pharmaceutical firms that create and promote targeted therapy for PNH dominate the region's PNH medication market. Companies like Alexion Pharmaceuticals, which is now a division of AstraZeneca, and the medicine eculizumab (marketed under the name Soliris), have had a substantial impact on the market environment. Additionally, the approval and availability of PNH medications are greatly influenced by the regulatory climate in North America, notably the United States. Targeted treatments for the treatment of PNH, such as eculizumab and ravulizumab (marketed under the brand Ultomiris), have been approved by the U.S. Food and Drug Administration (FDA), which has contributed to their extensive usage in the area.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:

Leading companies in the worldwide Deepwater Hydrocarbon Exploration market are stepping up their R&D efforts to diversify their product offerings. Additionally, these market participants use strategic alliances and partnerships that promote growth. The key players operating in the market include Ra Pharmaceuticals Inc, CinnaGen Co, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Apellis Pharmaceuticals, Abbott, NorthStar Rx LLC, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, Achillion Pharmaceuticals Inc and Amgen Inc.

Recent Developments:

In September 2023, the US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for crovalimab, an experimental, brand-new anti-C5 recycling monoclonal antibody, to treat paroxysmal nocturnal hemoglobinuria (PNH), according to Chugai Pharmaceutical Co., Ltd. The acceptance was based on the key phase III COMMODORE 2 study's findings, which showed that crovalimab effectively controlled illness and was well tolerated in PNH patients.1 Crovalimab's constant benefit-risk profile as seen in the phase III COMMODORE 1 study's findings provided additional evidence for the application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS

  • Ra Pharmaceuticals Inc
  • CinnaGen Co
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals
  • Abbott
  • NorthStar Rx LLC
  • Alnylam Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • BIOCAD
  • Samsung Bioepis
  • Amyndas Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • LGM Pharma.
  • Lannett
  • Achillion Pharmaceuticals Inc
  • Amgen Inc

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT

  • Medication
  • Supplements
  • Blood Transfusion
  • Bone Marrow Transplant

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS

  • Eculizumab
  • Ravulizumab
  • Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • Oral
  • Parenteral

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Treatment
    • 2.1.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Drugs
    • 2.1.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Route of Administration
    • 2.1.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by End User
    • 2.1.5. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Country
    • 2.1.6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends

  • 3.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Opportunities
  • 3.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Future Trends

4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape

  • 6.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Treatment

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
    • 7.1.2. Medication
    • 7.1.3. Supplements
    • 7.1.4. Blood Transfusion
    • 7.1.5. Bone Marrow Transplant

8. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Drugs

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drugs, 2022 & 2030 (%)
    • 8.1.2. Eculizumab
    • 8.1.3. Ravulizumab
    • 8.1.4. Others

9. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral

10. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Specialty Clinics
    • 10.1.5. Others

11. Paroxysmal Nocturnal Hemoglobinuria Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Ra Pharmaceuticals Inc
    • 12.2.2. CinnaGen Co
    • 12.2.3. Akari Therapeutics Plc
    • 12.2.4. Alexion Pharmaceuticals Inc
    • 12.2.5. Apellis Pharmaceuticals
    • 12.2.6. Abbott
    • 12.2.7. NorthStar Rx LLC
    • 12.2.8. Alnylam Pharmaceuticals Inc
    • 12.2.9. F. Hoffmann-La Roche Ltd
    • 12.2.10. Novartis AG
    • 12.2.11. Regeneron Pharmaceuticals Inc
    • 12.2.12. BIOCAD
    • 12.2.13. Samsung Bioepis
    • 12.2.14. Amyndas Pharmaceuticals
    • 12.2.15. Teva Pharmaceutical Industries Ltd.
    • 12.2.16. LGM Pharma.
    • 12.2.17. Lannett
    • 12.2.18. Achillion Pharmaceuticals Inc
    • 12.2.19. Amgen Inc

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Treatment Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Drugs Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drugs
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Region 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)